Please login to the form below

Not currently logged in
Email:
Password:

Forxiga

This page shows the latest Forxiga news and features for those working in and with pharma, biotech and healthcare.

Tecentriq’s triple negative breast cancer use among key CHMP nods

Tecentriq’s triple negative breast cancer use among key CHMP nods

AstraZeneca’s Forxiga gained European marketing authorisation to include use in patients with type 2 diabetes at risk of cardiovascular (CV) events. ... This follows results from its DECLARE-TIMI 58 trial, which compared the effect of Forxiga with

Latest news

More from news
Approximately 16 fully matching, plus 43 partially matching documents found.

Latest Intelligence

  • Leading AstraZeneca’s return to growth in Europe Leading AstraZeneca’s return to growth in Europe

    receiving treatment with SGLT-2 inhibitors, including AstraZeneca’s Forxiga (dapagliflozin).

  • The evolution of real-world studies The evolution of real-world studies

    AstraZeneca is putting its confidence in UK infrastructure to the test in a pragmatic trial designed to compare the effectiveness of diabetes drug Forxiga to the standard of care.

  • Biopharma's Future: Made in China Biopharma's Future: Made in China

    targeted lung cancer drug Tagrisso and diabetes treatment Forxiga.

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    Secondly, growth is ebbing away from Forxiga (dapagliflozin), the first entrant of the DPP4s, which is actually growing slightly slower than Trajenta. ... Forxiga and Invokana (canagliflozin) appear to be reaching a plateau but at different lower levels.

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    Between them, the companies developed the DPP-4 inhibitor Onglyza (saxagliptin), the saxagliptin/metformin combination product Kombiglyze and the SGLT2 inhibitor Forxiga (dapagliflozin), all of which have received approvals in various ... The potential

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics